Matt Campobasso - Enfusion General Counsel
| ENFN Stock | USD 10.13 0.11 1.10% |
Executive
Matt Campobasso is General Counsel of Enfusion
| Address | 125 South Clark Street, Chicago, IL, United States, 60603 |
| Phone | 312 253 9800 |
| Web | https://www.enfusion.com |
Matt Campobasso Latest Insider Activity
Tracking and analyzing the buying and selling activities of Matt Campobasso against Enfusion stock is an integral part of due diligence when investing in Enfusion. Matt Campobasso insider activity provides valuable insight into whether Enfusion is net buyers or sellers over its current business cycle. Note, Enfusion insiders must abide by specific rules, including filing SEC forms every time they buy or sell Enfusion'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Matt Campobasso over three months ago Disposition of 493 shares by Matt Campobasso of Enfusion at 8.95 subject to Rule 16b-3 |
Enfusion Management Efficiency
The company has return on total asset (ROA) of 0.0592 % which means that it generated a profit of $0.0592 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0548 %, meaning that it created $0.0548 on every $100 dollars invested by stockholders. Enfusion's management efficiency ratios could be used to measure how well Enfusion manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Tangible Assets is likely to grow to 0.06. Also, Return On Capital Employed is likely to grow to 0.14. At this time, Enfusion's Net Tangible Assets are very stable compared to the past year. As of the 28th of November 2024, Other Current Assets is likely to grow to about 7 M, while Total Assets are likely to drop about 88.2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Callan Young | ON24 Inc | N/A | |
| Elizabeth Rieveley | Meridianlink | N/A | |
| Brett Meager | Paycor HCM | N/A | |
| William Weesner | ON24 Inc | N/A | |
| Chad Anderson | Blackbaud | N/A | |
| Colleen Langevin | PROS Holdings | N/A | |
| Alice JD | Paycor HCM | 52 | |
| Kevin Smith | CS Disco LLC | 45 | |
| Dusty Buell | E2open Parent Holdings | N/A | |
| Michael Wu | PROS Holdings | N/A | |
| Priyanka Singh | Braze Inc | 55 | |
| Doug Piper | Meridianlink | N/A | |
| Michael Jahoda | PROS Holdings | 44 | |
| Tessa Barron | ON24 Inc | N/A | |
| Melanie Antoon | CS Disco LLC | 45 | |
| Philippa Lawrence | Freshworks | 57 | |
| Abbas Meghjee | ON24 Inc | N/A | |
| Rachel White | Paycor HCM | N/A | |
| Tiffany Sieve | Paycor HCM | N/A | |
| Mika Yamamoto | Freshworks | 51 | |
| Brian Wheeler | Braze Inc | N/A | |
Management Performance
| Return On Equity | 0.0548 | ||||
| Return On Asset | 0.0592 |
Enfusion Leadership Team
Elected by the shareholders, the Enfusion's board of directors comprises two types of representatives: Enfusion inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enfusion. The board's role is to monitor Enfusion's management team and ensure that shareholders' interests are well served. Enfusion's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enfusion's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stephen Dorton, Chief Officer | ||
| Michael Berry, Chief Officer | ||
| Lorelei Skillman, Chief Officer | ||
| Stephen Malherbe, Managing Partner | ||
| Oleg Movchan, Interim Director | ||
| Matthew Campobasso, General Secretary | ||
| Bronwen Bastone, Chief Officer | ||
| Joseph Defeo, Global Production | ||
| Kabir Kohli, MD Services | ||
| Jeff Young, Head Implementation | ||
| Brian Murphy, Investor | ||
| Matt Campobasso, General Counsel | ||
| Robert Taylor, Head Support | ||
| Ignatius Njoku, Head Relations | ||
| Bradley Herring, Chief Officer | ||
| Neal Pawar, Chief Officer | ||
| Daniel Groman, Chief Officer | ||
| Valeria Gutowski, Chief Officer |
Enfusion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enfusion a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0548 | ||||
| Return On Asset | 0.0592 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 918.44 M | ||||
| Shares Outstanding | 94.37 M | ||||
| Shares Owned By Insiders | 5.52 % | ||||
| Shares Owned By Institutions | 96.78 % | ||||
| Number Of Shares Shorted | 1.02 M | ||||
| Price To Earning | 0.11 X |
Pair Trading with Enfusion
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enfusion position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enfusion will appreciate offsetting losses from the drop in the long position's value.Moving together with Enfusion Stock
| 0.66 | U | Unity Software Aggressive Push | PairCorr |
| 0.65 | DJCO | Daily Journal Corp | PairCorr |
| 0.75 | AI | C3 Ai Inc Earnings Call This Week | PairCorr |
| 0.8 | BL | Blackline | PairCorr |
| 0.61 | DT | Dynatrace Holdings LLC | PairCorr |
Moving against Enfusion Stock
The ability to find closely correlated positions to Enfusion could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enfusion when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enfusion - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enfusion to buy it.
The correlation of Enfusion is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enfusion moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enfusion moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enfusion can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enfusion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.27) | Earnings Share 0.04 | Revenue Per Share 2.155 | Quarterly Revenue Growth 0.154 | Return On Assets 0.0592 |
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.